Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT3 receptors.

Brenda Costall1, Robert J Naylor

  • 1Bradford School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK.

Current Drug Targets. CNS and Neurological Disorders
|February 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus.

Archives of pharmacal research·2011
Same author

The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.

Basic & clinical pharmacology & toxicology·2008
Same author

Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.

Toxicology and applied pharmacology·2008
Same author

The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus.

Pharmacology, biochemistry, and behavior·2006
Same author

An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53.

Journal of pharmacological and toxicological methods·2006
Same author

Pharmacological characterization of endothelin receptors-mediated contraction in the mouse isolated proximal and distal colon.

British journal of pharmacology·2006
Same journal

Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.

Current drug targets. CNS and neurological disorders·2005
Same journal

Therapeutic perspectives of inhibitors of endocannabinoid degradation.

Current drug targets. CNS and neurological disorders·2005
Same journal

Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors.

Current drug targets. CNS and neurological disorders·2005
Same journal

Cannabinoids: between neuroprotection and neurotoxicity.

Current drug targets. CNS and neurological disorders·2005
Same journal

From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.

Current drug targets. CNS and neurological disorders·2005
Same journal

Endocannabinoids in neuroimmunology and stress.

Current drug targets. CNS and neurological disorders·2005
See all related articles

5-HT(3)-receptor antagonists are effective antiemetics, particularly for chemotherapy-induced nausea. These drugs also show promise for treating irritable bowel syndrome and other visceral pain disorders.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Neuroscience

Background:

  • 5-HT(3)-receptor antagonists are selective competitive inhibitors with high potency and rapid absorption.
  • They readily cross the blood-brain barrier and are metabolized by the cytochrome P450 system.
  • These compounds exhibit a favorable safety profile with minimal side effects like headache or constipation.

Purpose of the Study:

  • To review the clinical efficacy and potential applications of 5-HT(3)-receptor antagonists.
  • To explore their utility beyond antiemesis, including in gastrointestinal and visceral pain disorders.
  • To assess their role in psychiatric conditions and substance abuse.

Main Methods:

  • Review of preclinical data and clinical studies on 5-HT(3)-receptor antagonists.

Related Experiment Videos

  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Evaluation of efficacy and tolerability in various medical conditions.

    • Main Results:

    • Established efficacy in chemotherapy, radiotherapy, and post-operative emesis, setting a new standard for antiemetics.
    • Demonstrated clinical utility in irritable bowel syndrome and potential in other visceral pain disorders.
    • Preclinical studies suggest anxiolytic, cognitive-enhancing, and anti-dopaminergic effects, with limited but emerging use in substance abuse and withdrawal.

    Conclusions:

    • 5-HT(3)-receptor antagonists are highly effective antiemetics, significantly benefiting cancer patients.
    • Their potential in treating bowel disorders and visceral pain is promising.
    • While their use in psychiatric disorders appears limited, ongoing research may reveal further therapeutic applications.